Evidence-Based Complementary and Alternative Medicine

Research Article

Efficacy and Safety of the Two Ayurveda Drug Regimens in Uterine Fibroids: A Randomized Single-Blind Clinical Trial

Table 5

The safety outcomes of three arms.


Variable	Arm I (n = 35)	Arm II (n = 37)	Arm III (n = 30)

AST (IU/L)
Baseline	20.47 (9.45)	18.38 (6.39)	18.77 (8.15)
12^th week	20.13 (7.48)	18.87 (5.43)	18.40 (8.17)
value	0.78	0.63	0.31

ALT (IU/L)
Baseline	20.63 (10.30)	20.09 (9.01)	19.86 (11.19)
12^th week	20.90 (9.8)	19.38 (9.10)	19.71 (11.12)
value	0.84	0.54	0.35

Creatinine (mg/dl)
Baseline	0.68 (0.10)	0.63 (0.10)	0.69 (0.14)
12^th week	2.1 (8.67)	2.04 (8.44)	0.69 (0.14)
value	0.33	0.31	0.20

GFR (mL/min/1.73 m²)
Baseline	>90	>90	>90
12th week	>90	>90	>90

Urobilinogen (mg/dL)
Baseline	Normal	Normal	Normal
12^th week	Normal	Normal	Normal

Bile pigments
Baseline	Nil	Nil	Nil
12^th week	Nil	Nil	Nil

WBC (10^9/L)
Baseline	28.34 (107.48)	28.47 (121.42)	24.19 (101.11)
12^th week	28.64	28.25	26.30

PLT (10^9/L)
Before	343 .57 (80.30)	339.41 (89.87)	331.63 (86.73)
12^th week	354.71 (69.74)	342.22 (77.77)	339.03 (88.78)

Hematocrit (%)
Before	34.52 (4.89)	37.48 (5.17)	36.29 (4.34)
12^th week	36.65 (9.67)	37.47 (8.63)	36.38 (4.26)

Values are presented as mean ± standard deviation. AST, aspartate transaminase; ALT, alanine aminotransferase; GFR, glomerular filtration rate; TB, total bilirubin; WBC, white blood cells; PLT, platelet. Based on urine full report. Based on full blood count. Significant level of by the paired t-test.